Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A cobalt-porphyrin complex having the structure:

$$R_3$$
 CH_3
 R_4
 CH_3
 R_1
 R_2
 R_1
 R_2

or a salt thereof, wherein:

 R_1 and R_2 are both -(CH₂)₂C(=O)OCH(CH₃)₂; the same or different and independently -(CH₂)_n-A-R₅, wherein A is -C(=O)O-, -OC(=O)-, -C(=O)N(R)-, -N(R)C(=O)-, -C(=O)-, -N(R)-, -O- or -S-, and R is hydrogen, alkyl, substituted alkyl, arylalkyl, or substituted arylalkyl, and n is 2 or 3;

R₃ and R₄ are <u>both</u> the same or different and independently -CH=CH₂ or -CH₂CH₃; and

 R_5 is, at each occurrence, the same or different and independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl or substituted arylalkyl; and

L₁ and L₂ are both glycinate. optional ligands;

and with the proviso that the cobalt-porphyrin complex of structure (I) has no more than 5% of the redox activity of cobalt mesoporphyrin.

2-30. (Cancelled)

- 31. (Original) A composition comprising a compound of claim 1 in combination with a pharmaceutically acceptable carrier.
- 32. (Currently Amended) A method for treating obesity, comprising administering an effective amount of a composition comprising a cobalt-porphyrin complex and a pharmaceutically acceptable carrier, wherein the cobalt-porphyrin complex has the structure:

$$R_3$$
 CH_3
 CH_3

or a salt thereof, wherein:

 R_1 and R_2 are both -(CH₂)₂C(=O)OCH(CH₃)₂; the same or different and independently -(CH₂)_n-A-R₅; wherein A is -C(=O)O-, -OC(=O)-, -C(=O)N(R)-, -N(R)C(=O)-, -C(=O)-, -O- or -S-, and R is hydrogen, alkyl, substituted alkyl, arylalkyl, or substituted arylalkyl, and n is 2 or 3;

 R_3 and R_4 are <u>both</u> the same or different and independently -CH=CH₂ or -CH₂CH₃; and

 R_s is, at each occurrence, the same or different and independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl or substituted arylalkyl; and

L₁ and L₂ are both glycinate. optional ligands;

and with the proviso that the cobalt-porphyrin complex of structure (I) has no more than 50% of the redox activity of cobalt mesoporphyrin.

Application No. 10/020,867 Reply to Office Action mailed May 6, 2004

33-62. (Cancelled)